A phase II study of nab-paclitaxel plus ramucirumab for the second-line treatment of patients with metastatic gastroesophageal cancer.

Johanna C. Bendell,Ivor John Percent,Robert Weaver,Cynthia Coo Chua,Henry Q. Xiong,Allen Lee Cohn,Ahmed Zakari,Jaswinder Singh,Mark Kozloff,Caressa Lietman,Cassie M. Lane,Suzanne F. Jones,L Finney,Sean Carmody,Mark Sanders Womack

A phase II study of nab-paclitaxel plus ramucirumab for the second-line treatment of patients with metastatic gastroesophageal cancer.

2020

Johanna C. Bendell
Ivor John Percent
Robert Weaver
Cynthia Coo Chua
Henry Q. Xiong
Allen Lee Cohn
Ahmed Zakari
Jaswinder Singh
Mark Kozloff
Caressa Lietman
Cassie M. Lane
Suzanne F. Jones
L Finney
Sean Carmody
Mark Sanders Womack

365Background: Nab-paclitaxel (NP) is a protein-stabilized formulation of paclitaxel, US FDA approved for treatment of metastatic breast cancer, advanced/metastatic non-small cell lung cancer and m...

Keywords:

Internal medicine
Gastroesophageal cancer
Phases of clinical research
Nab-paclitaxel
Oncology
Medicine
Pathology
Ramucirumab
second line treatment
Metastatic breast cancer
Paclitaxel
non small cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations